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overall survival: 99,1% (1 group) vs. 97,7% (2 group) and 97,8% (3 
group), (p< 0.216). Five-year event free survival: 98,0% (1 group) vs. 
92,2% (2 group)and 94,5% (3 group), (p < 0.0345). Only 8% of the 
patients of the 1 group developed grade 2 erythema , 17,7% of the 
patients of the 2 group (p=0.043) and 14,3% of the patients of the 3 
group (p<0,048). Side effects after 5 years: 35,7% (1 group) vs. 53,8% 
(2 group) and 42,8% (3 group), (p < 0.05). Excellent and good cosmetic 
results after 5 years: 79,4% (1 group) vs. 65,4% (2 group) and 73,6% (3 
group), (p < 0.049). 
Results: No difference in distant metastasis and overall survival 
between different regimes of RT. 
Conclusions: Accelerated hypofractionated RT (3 Gy per fraction over 
2,5 weeks, total dose of 39Gy) decrease in local relapse, acute 
toxicity and adverse effects, increase five-year event free survival and 
cosmetic results after accelerated hypofractionated vs. dynamic 
hypofractionated and standard radiation treatment.  
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Purpose/Objective: Whole breast irradiation(WBI) (50 Gy in 25 daily 
fractions of 2 Gy over 5 weeks ± boost of 10 Gy to the tumor bed) is 
the standard treatment after breast-conserving surgery (BCS) for early 
breast cancer (EBC). Recent randomized trials have confirmed that 
hypofractionated whole breast irradiation (WB-HyRT) is an effective 
alternative to conventional WBI for its equivalence in terms of local 
tumorcontrol, patients survival and late post-radiation effects. The 
aim of our experience was to evaluate feasibility, compliance and 
acute and early late toxicity of WB-HyRT. 
Materials and Methods: From February 2011 to November 2012, 41 
patients with EBC (pT1-2, pN0-1, pM0), who underwent BCS and 
sentinel nodal examination with or without axillary dissection, were 
treated with adjuvant WB-HyRT using 3D conformal radiotherapy. The 
median age was 73 years (range 60-84). The whole breast was treated 
with two opposed tangential fields, for a total dose of 42.56 Gy in 16 
daily fractions (2.66 Gy/f), with Linac 6 MV. Five patients received 
chemotherapy antracicline and taxan based, before RT. 36 patients 
received adjuvant hormonal therapy (FATA protocol), because the five 
remaining cases had hormone receptors negative. Toxicity was 
evaluated according to RTOG/EORTC toxicity criteria. The acute 
toxicity (within 6 months after the end of RT) was evaluate during RT 
course with weekly clinical examination, and early late toxicity wase 
stimated during standard follow-up.  
Results: the mean follow-up was 9 months (1-21 range). All patients 
completed radiotherapy without break for toxicity end with a good 
compliance to the treatment. All patients were evaluated for acute 
toxicity and 21 for early late toxicity. Acute skin toxicity was G3 in 1 
patient (2,4%), G2 in 6 pts (14,6%), G1 in 26 pts (63,4%) and G0 in 8 
pts (19,5%). Acute hematological toxicity was G3 in 2 pts (5%), G1 in 3 
pts (7,3%), G0 in 36 pts (87,7%) and none G2. None patients suffered 
from cardiac or pulmonary or other acute toxicity. Early late skin 
toxicity observed was G1 in 5 pts (23,8%) and G0 in16 pts (76,2%). 
Only one (4,2%) patient had G1 early late hematological toxicity. No 
other early late toxicity were register. 
Conclusions: Our results showed that WB-HyRT is feasible and well 
tolerated, with few acute and early late toxicity and good compliance 
to the treatment. In older women with EBC the hypofractionated 
schedule represent a biologically acceptable alternative to the 
traditional 6 weeks regime. Also the reduction of the overall 
treatment time leads advantages in economic saving terms and can 
have a benefit in LINAC waiting list too. 
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Purpose/Objective: Whilst 3dCRT is widely used for the adjuvant 
treatment of breast cancers, the use of ARC therapy using Helical 
Tomotherapy(HT) is gaining momentum in specific centres. 
Materials and Methods: Two Radiotherapy(RT) plans (HT and 3DCRT) 
for ten adjuvant chest wall and breast including supraclavicular fossa 
(SCF) treatment were compared. Dose to target volumes (TV) 
including SCF (2 with gross nodes requiring boost), internal mammary 
chain(IMC, 3 patients), lung,heart, brachial plexus were compared. 
Homogeneity index (HI) and conformityindex (CI) was calculated for 
TV coverage. A hypofractionated 40Gy in 15fraction schedule was 
prescribed to the PTV.  
Results: TV coverage both for chest wall and whole breast(n=2) was 
better with HT; median dose (±SD) of 41.58Gy (±1.92) for HT and 
38.97(±3.41)using 3DCRT; p=0.01. SCF median dose 41.62Gy (±2.85) 
vs. 31.86Gy (±12.34)respectively (p-0.04) was better with HT whilst 
IMC coverage too was betterwith HT. HI and CI were both better with 
HT than 3dCRT. Brachial plexus received higher maximum 
(41.31Gy/33.99Gy) and median dose (17.34Gy/4.96Gy) with HT. The 
mean dose to the heart was higher with HT than 3DCRT; 5.65Gy versus 
0.79Gy for right sided tumours(n=4) and 9.69Gy vs.1.69Gy for left 
sided tumours(n=6) without IMC coverage(n=3) and 11.56 Gy vs.2.34 
Gy for left sided tumours with IMC coverage(3DCRT plans generated 
without IMC coverage). For left sided tumours with IMC irradiation, 
the V15Gy and V20Gy(mean±SD) of the heart was significantly higher 
with HT (24.55±12.18% vs.4.35±1.95% and 15.83±9.51 vs.3.96±1.78%) 
respectively..Those without IMC coverage,the mean V15Gy and V20 Gy 
of heart was 21.62% vs.5.38% and 10.42% vs.4.82% respectively. 
Contralateral mean lung dose was also higher with HT (3.38Gy 
vs.0.22Gy).Mean V5Gy and V15Gy of contralateral lung was 19.17% 
vs.0% and 1.3% vs. 0% respectively in HT versus 3dCRT. The opposite 
breast too received a higher mean dose with HT than 3DCRT (7.02Gy 
vs. 0.26Gy) 
Conclusions: HT provided a better target volume coverage including 
coverage of IMC and SCF and Breast/Chest wall without the use of 
field junctions. The better CI with HT was achieved at the expense of 
higher mean dose to the OARs like heart, contralateral lung, opposite 
breast and brachial plexus. Dosimetric data suggests little evidence 
for the routine use of HT in adjuvant breast radiotherapy but it could 
be considered in selected complex volumes including when treating 
the IMC, SCF and boosting gross residual disease post chemotherapy. 
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Purpose/Objective: Localization of the tumor bed of breast cancer is 
crucial for accurate planning of boost irradiation. Lumpectomy cavity 
and surgical clips provide localizing information about tumor bed. 
However, defining the tumor bed is often difficult because of 
presence of unclear lumpectomy cavity and lack of certain 
information such as absence of surgical clips. In the present study, we 
evaluated the role of diagnostic PET-CT in localization of the tumor 
bed using deformable image registration (DIR). 
Materials and Methods: We selected twenty-five patients who had a 
preoperative PET-CT performed and underwent breast-conserving 
surgery with surgical clips in tumor bed. In every individual patient, 
two target volumes were separately delineated on planning CT; 1) 
planning target volume based on surgical clips with a margin of 1 cm 
(PTVclip) and 2) gross tumor volume based on 90% of maximum SUV on 
PET-CT registered by DIR (GTVPET). The percent of GTVPET in PTVclip 
(Vin) was calculated and distance between center points of two 
volumes (Dcenter) was also measured. 
Results: Mean Dcenter between two volumes was 1.4 cm (range, 0.33 – 
2.53). Mean Vin was 94.8% (range, 60.9-100) and 100% in 18 out of 25 
patients. When compared to the center of PTVclip, the center of GTVPET 
tended to be located posteriorly (mean 0.3 cm, standard deviation 
0.6), laterally (mean 0.3cm, standard deviation 0.8) and inferiorly 
(mean 0.4 cm, standard deviation 0.9). 
Conclusions: DIR of diagnostic PET-CT can be a considerable 
reference for the localization of tumor bed on planning CT for breast 
cancer radiotherapy. 
 
 ELECTRONIC POSTER: CLINICAL TRACK: GASTRO-
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